Active ingredientRadotinibCat. No. P-R004-001CAS 926037-48-1Family · Pharmaceutical analytical standards
Radotinib
An oral Bcr-Abl tyrosine kinase inhibitor developed in South Korea and approved there in 2012 for Philadelphia chromosome-positive chronic myeloid leukaemia, when first-generation drugs such as imatinib fail or are not tolerated. This family brings together the active ingredient and labelled standards.
Did you know?In 2018 a mouse study showed that it reaches the brain effectively and protects neurons in a model of Parkinson's disease: since then it has also been studied in this condition.
Go to the active ingredient →Active ingredientRadotinibCat. No. P-R004-001CAS 926037-48-1
Isotopically labelledRadotinib-d6Cat. No. P-R004-002CAS 2754051-83-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.